Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin added to standard chemoradiotherapy for MGMT-unmethylated newly diagnosed refractory glioblastoma
ChiCTR-IIR-17010327Phase 2Recruiting
- Sponsor
- Shanghai Jing'an District Central Hospital
- Start
- Jan 2017
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin and temozolomide in glioblastoma (GBM) (2 arms), sponsored by Shanghai Jing'an District Central Hospital. Primary endpoints: Progression-free survival, Overall survival and 1 more. Started Jan 2017; status: recruiting.
02
Drugs
cisplatintemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR-IIR-17010327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17010327.